ArticlePlant foods for human nutrition (Dordrecht, Netherlands)2026
A Novel Chestnut Protein Hydrolysate-Zinc Chelate: Chelation Mechanism, Antioxidant, Bioaccessibility and Cytotoxicity.
Article in Plant foods for human nutrition (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Zinc is an essential micronutrient which must be obtained through dietary intake or supplementation, while its biological accessibility in the human body is limited by phytic acid and others. To develop highly bioavailable zinc supplements, chestnut protein hydrolysate (CPH) was used to prepare a novel chestnut protein hydrolysate-zinc chelate (CPH-Zn), and the zinc chelation efficiency of CPH-Zn was 53.85 ± 5.31%. Characterization results revealed that zinc binding induced the conformational changs in CPH by coordinating with carboxy oxygen, nitrogen atoms of amide, and nitrogen atoms of amino groups. In addition, zinc chelation significantly altered the surface charge of peptide, and the chelate exhibited a porous network with increased surface roughness. Moreover, the CPH-Zn demonstrated superior antioxidant activities and low cytotoxicity at concentrations below 0.6 mg/mL. Notably, during simulated gastrointestinal digestion, zinc solubility of CPH-Zn (17.14 ± 1.91%) was significantly higher than that of ZnSO4 (6.73 ± 0.56%). These results presented the transformation of a chestnut by-product into CPH-Zn as a safe chelate that overcame bioaccessibility limitations, providing an effective zinc supplementation in human nutrition and animal feed.
Indexed as
Identifiers
41748969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.